李克强:精准做好常态化防控,进一步加强疫苗药物和检测试剂研发工作

2020-06-04 佚名 中国政府网

6月4日,中共中央政治局常委、国务院总理、中央应对新冠肺炎疫情工作领导小组组长李克强主持召开领导小组会议。

6月4日,中共中央政治局常委、国务院总理、中央应对新冠肺炎疫情工作领导小组组长李克强主持召开领导小组会议。

中共中央政治局常委、中央应对新冠肺炎疫情工作领导小组副组长王沪宁出席。

会议指出,要认真贯彻习近平总书记重要讲话精神,按照中央应对疫情工作领导小组部署,继续抓实抓细内防反弹各项措施,根据境外疫情变化做好外防输入工作,提升防控和救治能力,加快健全公共卫生体系,持续巩固疫情防控成果,加大复商复市复学推进力度,全面恢复经济社会秩序。

会议指出,今年全国两会期间,有关地方和部门扎实做好疫情防控各项工作,保障了会议顺利进行。当前我国疫情形势总体稳定,但近两周个别地方仍有零星散发病例,全国仍有一定数量无症状感染者,境外疫情输入风险不容忽视。下一步,要继续落实常态化防控措施,加强无症状感染者医学管理,坚持实事求是、公开透明发布疫情信息。各地要认真总结常态化防控经验做法,根据国内生产生活秩序恢复、国际人员往来可能增多的情况,阶段性动态调整、精准优化和落实防控措施。国务院联防联控机制要加强指导,推进旅游、文化、体育等行业扩大复工复业。当前各地加快全面复学,要督促各类学校严格落实校园疫情防控技术方案和指引,针对中考、高考等关键时间节点细化全流程防控措施,加强应急演练和相关防疫物资人员准备。

会议指出,在各方面共同努力下,我国新冠病毒检测能力不断提升。目前核酸检测能力超过每天300万人份。要继续做好重点人群应检尽检和其他人群愿检尽检工作,抓紧补上一些地区疾控机构、医院等检测能力短板,特别要加大快速检测试剂和移动便捷设备研发生产力度,便利在更多需要的场合开展检测。要强化防控应急处置、医疗救治能力建设和防疫物资储备。进一步推进疫苗和有效药物科研攻关,加强国际合作。目前相关疫苗研发试验已取得阶段性成效,要尊重科学规律,依法合规积极推进各阶段临床试验,力争尽快取得突破,为维护人民健康提供有力保障。

领导小组成员丁薛祥、孙春兰、黄坤明、蔡奇、王毅、肖捷、赵克志参加会议。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659767, encodeId=a7231659e6728, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Tue Aug 25 21:07:17 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934661, encodeId=fc951934661fd, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Feb 12 03:07:17 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300393, encodeId=e0931300393ad, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403503, encodeId=f4d714035039d, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659767, encodeId=a7231659e6728, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Tue Aug 25 21:07:17 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934661, encodeId=fc951934661fd, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Feb 12 03:07:17 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300393, encodeId=e0931300393ad, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403503, encodeId=f4d714035039d, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659767, encodeId=a7231659e6728, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Tue Aug 25 21:07:17 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934661, encodeId=fc951934661fd, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Feb 12 03:07:17 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300393, encodeId=e0931300393ad, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403503, encodeId=f4d714035039d, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=)]
    2020-06-06 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659767, encodeId=a7231659e6728, content=<a href='/topic/show?id=d90c48602f2' target=_blank style='color:#2F92EE;'>#常态化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48602, encryptionId=d90c48602f2, topicName=常态化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f80725025635, createdName=mxj1971620, createdTime=Tue Aug 25 21:07:17 CST 2020, time=2020-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934661, encodeId=fc951934661fd, content=<a href='/topic/show?id=325762560c5' target=_blank style='color:#2F92EE;'>#检测试剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62560, encryptionId=325762560c5, topicName=检测试剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Feb 12 03:07:17 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300393, encodeId=e0931300393ad, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403503, encodeId=f4d714035039d, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sat Jun 06 13:07:17 CST 2020, time=2020-06-06, status=1, ipAttribution=)]

相关资讯

Lancet:重组腺病毒新冠肺炎疫苗I期临床获得成功

重组腺病毒5型(AD5) COVID-19疫苗具有较好的耐受性,在注射后28天可产生免疫性

如何与新冠病毒长期相处?“抗击COVID-19一线经验与战略的多边分享”会专家提出建议

如何与新冠病毒长期相处?钟南山院士在全球抗击新冠病毒肺炎联盟首场研讨会“抗击COVID-19一线经验与战略的多边分享”会上认为,“疫苗”是获取群体免疫最佳路径。

陈薇团队疫苗研发,还有哪些关卡要闯?

“这些结果是一个重要的里程碑。”军事科学院军事医学研究院生物工程研究所的陈薇院士说。

Lancet:陈薇团队首次COVID-19疫苗人体试验结果:安全,可诱导快速免疫反应

导言:新冠疫情仍在全球蔓延,疫苗的研发进程可能直接决定了这场抗疫战的持续时间,也将对全球经济、政治产生深刻的影响。早在3月16日,陈薇院士团队研制的新冠疫苗就通过了临床研究注册审评,获批进入临床试验。

J Infect Dis:HSV529疫苗可有效且安全用于预防单纯疱疹病毒2感染

单纯疱疹病毒2(HSV2)导致全球有4亿多人感染生殖器疱疹。